[Posts Record Revenue & Highest-Ever EPS for FY26]
Windlas Biotech Limited · WINDLAS · NSE ·
**FY26 Performance:** Revenue from operations grew 19% YoY to ₹904 crores, with reported Profit After Tax (PAT) at ₹66 crores (up 9% YoY). **Record Earnings:** Achieved the highest post-listing EPS of ₹31.60. **Segment Growth:** The core CDMO business grew 20%, while the Exports…